Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

YIV 906

Drug Profile

YIV 906

Alternative Names: KD018; PHY-906; YIV-906

Latest Information Update: 08 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PhytoCeutica
  • Developer Kadmon Corporation; PhytoCeutica; Yale University; Yiviva
  • Class Chemoprotectants
  • Mechanism of Action Acetylcholinesterase modulators; Cyclo-oxygenase 2 inhibitors; Cytochrome P 450 enzyme system inhibitors; Metalloprotease inhibitors; NF-kappa B inhibitors; Nitric oxide synthase type II inhibitors; Opioid delta receptor antagonists; P-glycoprotein inhibitors; Tachykinin receptor antagonists; Wnt signalling pathway modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Liver cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase II Colorectal cancer; Liver cancer
  • Phase I/II Pancreatic cancer
  • Clinical Phase Unknown Rectal cancer
  • Preclinical Inflammatory bowel diseases; Irritable bowel syndrome; Malignant melanoma; Non-small cell lung cancer
  • Discontinued Gastrointestinal disorders

Most Recent Events

  • 05 Feb 2024 Yiviva completes enrolment in its phase II CALM trial for Liver cancer in USA, China, Hong Kong, and Taiwan (NCT04000737)
  • 11 Oct 2023 Clinical trial in Rectal cancer (Neoadjuvant therapy) is still ongoing in USA (PO) (Yiviva pipeline, October 2023)
  • 11 Oct 2023 Preclinical trials in Inflammatory bowel diseases in USA (PO), prior to October 2023 (Yiviva pipeline, October 2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top